Blog

Central Laboratories virtual clinical trials

February 6, 2023 Chuck Drucker

At-home Self-collection of Blood Specimens for Safety Lab Testing in Clinical Trials via the Tasso+ Device

Supporting virtual clinical trials with laboratory services that focus on easing patient and site burden by way of innovative self-collection technology.

Central Laboratories

January 27, 2023 Stephanie Larimer

What are the opportunities for decentralized clinical trials

Hybrid and decentralized clinical trials (DCTs) are fast becoming the norm, but they often involve multiple vendors and service providers, presenting sponsors and CROs with new considerations on the...

Central Laboratories

January 27, 2023 Chuck Drucker

Integrating Self-Collection Lab Panels: The Clinical Lab Perspective

With recent advancements in the self-collection of blood allowing trial participants to provide blood specimen for lab testing from the comfort of their home, Q² Solutions’ Chuck Drucker recently...

Clinical Trial Sample and Consent Tracking

January 18, 2023 BioFortis

Moving from chaos to calm: How a complete CTST solution can simplify your clinical trials

You feel like a ball of anxiety from the beginning to the end of your clinical trials. You have so many competing priorities that you don’t have time to learn new technology. You want to build...

Clinical Trial Sample and Consent Tracking

January 4, 2023 BioFortis

Clinical trial consent: Using automation to get it right —every time

“We have 20,000 samples and don’t know what they’re for or where they’re from!”

Clinical Trial Sample and Consent Tracking Labmatrix

December 19, 2022 BioFortis

Clinical trial sample and consent tracking in the Digital Age

Moving from pen and paper to automated tech

Genomics

October 17, 2022 Wendell Jones, Ph.D.

PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer

NAR Cancer article, with contributions from Wendell Jones, PhD, Q² Solutions GenomicsUterine serous carcinoma (USC), an aggressive variant of endometrial cancer representing approximately 10% of...

Infectious Diseases

October 13, 2022 Patrice Hugo, Ph.D.

What are the key ingredients for a best practice R&D approach for tackling infectious disease?

With a renewed interest in vaccine research and development (R&D), stakeholders across the industry are rethinking their approach to the field. Biopharmaceutical companies have growing numbers of...

Infectious Diseases Vaccines

October 10, 2022 Patrice Hugo, Ph.D.

Balancing R&D for Disease X and common illnesses

Stakeholders from across the industry, including biopharmaceutical companies, governments, and non-profit organizations, are rethinking their pandemic readiness in light of the COVID-19 pandemic,...

Central Laboratories

August 19, 2022 Steven Lobel, PhD, D-ABMLI, MBA, FACB

The Genesis of the Estimated Glomerular Filtration Rate (eGFR)

In the beginning there was urine, creatinine and 3-liter jugs.

Blog

Filter By Topic

Search Blog Articles

At-home Self-collection of Blood Specimens for Safety Lab Testing in Clinical Trials via the Tasso+ Device

What are the opportunities for decentralized clinical trials

Integrating Self-Collection Lab Panels: The Clinical Lab Perspective

Moving from chaos to calm: How a complete CTST solution can simplify your clinical trials

Clinical trial consent: Using automation to get it right —every time

Clinical trial sample and consent tracking in the Digital Age

PLK3 amplification and tumor immune microenvironment of metastatic tumors are linked to adjuvant treatment outcomes in uterine serous cancer

What are the key ingredients for a best practice R&D approach for tackling infectious disease?

Balancing R&D for Disease X and common illnesses

The Genesis of the Estimated Glomerular Filtration Rate (eGFR)